Key Points
- Max Rosett, Immunome's CFO, sold 65,000 shares on April 2 at an average price of $21.92 for about $1.4248 million, a transaction disclosed on the SEC Form 4 and executed under a Rule 10b5-1 trading plan.
- The sale reduced Rosett's direct ownership by 54.6%, leaving him with 54,037 shares valued at roughly $1.18 million after the trade.
- Immunome has a market cap of about $2.47 billion, a 52-week range of $5.15–$27.65, reported negative recent earnings (Q1 EPS -$0.75), and holds a MarketBeat consensus rating of "Moderate Buy" with an average target near $33.45.
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) insider Jack Higgins sold 9,438 shares of the firm's stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $21.64, for a total transaction of $204,238.32. Following the completion of the sale, the insider owned 22,000 shares of the company's stock, valued at $476,080. The trade was a 30.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Immunome Stock Performance
Shares of IMNM stock opened at $21.84 on Friday. Immunome, Inc. has a 1 year low of $5.15 and a 1 year high of $27.65. The firm's 50 day moving average is $22.34 and its 200-day moving average is $19.22. The firm has a market capitalization of $2.47 billion, a price-to-earnings ratio of -9.02 and a beta of 2.13.
Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.10). On average, equities research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Assetmark Inc. bought a new position in shares of Immunome in the 3rd quarter worth $39,000. BNP Paribas Financial Markets increased its holdings in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock valued at $60,000 after purchasing an additional 2,909 shares during the last quarter. Strs Ohio acquired a new position in Immunome in the fourth quarter valued at about $64,000. Tower Research Capital LLC TRC lifted its stake in Immunome by 121.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock valued at $65,000 after buying an additional 3,802 shares during the period. Finally, BIT Capital GmbH bought a new position in Immunome during the third quarter worth about $69,000. Institutional investors and hedge funds own 44.58% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on IMNM shares. Wedbush reissued an "outperform" rating and issued a $31.00 target price on shares of Immunome in a research note on Thursday, January 15th. Evercore upped their price target on Immunome from $18.00 to $40.00 and gave the company an "outperform" rating in a research note on Tuesday, December 16th. Leerink Partners set a $40.00 price target on Immunome in a report on Monday, December 15th. Wall Street Zen lowered Immunome from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. Finally, Guggenheim boosted their price objective on Immunome from $25.00 to $35.00 and gave the stock a "buy" rating in a report on Tuesday, December 16th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $33.45.
Get Our Latest Analysis on IMNM
About Immunome
(
Get Free Report)
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
